MedTrace Logo

Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia

NCT04177680 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-03-04

Study results available
· View outcomes & findings →

Summary

Pharmacodynamic effects of MAT9001 compared to Vascepa in adults with hypertriglyceridemia

Conditions

  • Hypertriglyceridemia

Interventions

DRUG

Omega 3 pentaenoic acid

Encapsulated omega-3 pentaenoic acid

DRUG

icosapent ethyl

Encapsulated omega-3 acid ethyl esters

Sponsors & Collaborators

  • Matinas Biopharma, Inc

    collaborator INDUSTRY

  • MB Clinical Research and Consulting LLC

    collaborator UNKNOWN

  • Matinas BioPharma Nanotechnologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Kevin Maki · MB Clinical Research and Consulting

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-03
Primary Completion
2020-11-27
Completion
2021-01-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04177680 on ClinicalTrials.gov